The Medical Letter on Drugs and Therapeutics
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
The full article is available to subscribers Subscriber Login   

The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD).

EVOLOCUMAB — Evolocumab is a human IgG2 monoclonal antibody injected subcutaneously every two weeks or once monthly. It targets PCSK9 (proprotein convertase subtilisin kexin type 9) and prevents it from binding to LDL receptors, resulting in increased LDL receptor expression and increased hepatic uptake of LDL-cholesterol (LDL-C). Like alirocumab (Praluent), the other FDA-approved PCSK9 inhibitor, evolocumab has been found to reduce LDL-C levels by about 55-60% when added to statin therapy, and it is generally well tolerated.1 Alirocumab has not yet been shown to improve cardiovascular outcomes. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Reduction of Cardiovascular Risk with Evolocumab (Repatha)
Article code: 1519a
 Electronic, downloadable article - $25